Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 4, 2011, Pages

  Bruce, Robert Douglas ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BUPRENORPHINE;

DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INHIBITION; HUMAN; LETTER; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

ANTI-HIV AGENTS; BUPRENORPHINE; DRUG-INDUCED LIVER INJURY; HIV INFECTIONS; HUMANS; NALOXONE; OPIOID-RELATED DISORDERS;

EID: 80155145567     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31822c1d28     Document Type: Letter

References (3)

1. Vergara-Rodriguez P, Tozzi MJ, Botsko M, et al. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr. 2011;56(suppl 1):S62-S67.
2. Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. Aids. 2006;20:783-784. (Pubitemid 43884310)
3. McCance-Katz EF, MoodyDE, MorseGD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007;91:269-278. (Pubitemid 47539730)